Article Text

Download PDFPDF

395 Outcomes of carbotaxol in carcinosarcoma: a retrospective study at the brazilian national cancer institute (INCA)
  1. L Albuquerque1,
  2. J Lope da Silva2,
  3. A Letícia Gasparotto3,
  4. B Regina Lima de Aguiar4,
  5. D de Sousa Barros Rodrigues5,
  6. T Costa Farias6 and
  7. A Cristina de Melo2
  1. 1Universidade Federal Fluminense, Faculdade de Medicina, Rio de Janeiro, Brazil
  2. 2Instituto Nacional de Câncer, Divisão de Pesquisa Clinica e Desenvolvimento Tecnológico, Rio de Janeiro, Brazil
  3. 3Universidade Federal do Paraná, Faculdade de Medicina, Paraná, Brazil
  4. 4Universidade de Brasilia, Departamento de Enfermagem, Distrito Federal, Brazil
  5. 5Universidade Federal da Paraíba, Programa de pós-graduação em Fonoaudiologia, João Pessoa, Brazil
  6. 6Universidade Federal de Campina Grande, Faculdade de Medicina, Paraíba, Brazil


Objectives Endometrial carcinosarcomas (EC) are rare metaplastic tumors with dual composition of mesenchymal and epithelial elements, seen as a good example of epithelial-mesenchymal transition (EMT). The current study evaluated the efficacy and safety of Carbotaxol (CT) as adjuvant and first-line (1L) palliative treatment for women with carcinosarcoma.

Methods This retrospective cohort of patients (pts) with EC treated with 3qw Carbotaxol at INCA between January 2012 and January 2017 assessed overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), response rate (RR), and tolerability. All analyses were performed with the SPSS software, version 18.0.

Results A total of 48 pts were enrolled, median age 66.1 years, mostly with stage III disease (43.8%). The median OS for all pts was 21.5 m. For stage IV, OS was 11.1 m. The median DFS for pts treated with adjuvant CT was 20.5 m. For the 21 stage IV pts treated with 1L CT, the median PFS was 6.9 m and median OS was 12.3 m; partial response occured in 9.5%, stable disease in 28.6% and disease progression in 57.1%. The main side effects were asthenia, alopecia, vomiting and myelotoxicity.

Conclusions The combination of carboplatin and paclitaxel has been shown to be effective and safe for the treatment of EC. Staging was confirmed as a strong prognostic factor. The adverse events were manageable and there were no chemo-related deaths. The results were quite similar to those previously reported by multicenter studies.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.